Journal article
Equations to predict antimicrobial minimum inhibitory concentrations in Neisseria gonorrhoeae using molecular antimicrobial resistance determinants
- Abstract:
- The emergence of Neisseria gonorrhoeae strains that are resistant to azithromycin and extended-spectrum cephalosporins represents a public health threat, that of untreatable gonorrhea infections. Multivariate regression modeling was used to determine the contributions of molecular antimicrobial resistance determinants to the overall antimicrobial MICs for ceftriaxone, cefixime, azithromycin, tetracycline, ciprofloxacin, and penicillin. A training data set consisting of 1,280 N. gonorrhoeae strains was used to generate regression equations which were then applied to validation data sets of Canadian (n = 1,095) and international (n = 431) strains. The predicted MICs for extended-spectrum cephalosporins (ceftriaxone and cefixime) were fully explained by 5 amino acid substitutions in PenA, A311V, A501P/T/V, N513Y, A517G, and G543S; the presence of a disrupted mtrR promoter; and the PorB G120 and PonA L421P mutations. The correlation of predicted MICs within one doubling dilution to phenotypically determined MICs of the Canadian validation data set was 95.0% for ceftriaxone, 95.6% for cefixime, 91.4% for azithromycin, 98.2% for tetracycline, 90.4% for ciprofloxacin, and 92.3% for penicillin, with an overall sensitivity of 99.9% and specificity of 97.1%. The correlations of predicted MIC values to the phenotypically determined MICs were similar to those from phenotype MIC-only comparison studies. The ability to acquire detailed antimicrobial resistance information directly from molecular data will facilitate the transition to whole-genome sequencing analysis from phenotypic testing and can fill the surveillance gap in an era of increased reliance on nucleic acid assay testing (NAAT) diagnostics to better monitor the dynamics of N. gonorrhoeae.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 409.6KB, Terms of use)
-
- Publisher copy:
- 10.1128/AAC.02005-19
Authors
- Publisher:
- American Society for Microbiology
- Journal:
- Antimicrobial Agents and Chemotherapy More from this journal
- Volume:
- 64
- Issue:
- 3
- Article number:
- e02005-19
- Publication date:
- 2019-12-23
- Acceptance date:
- 2019-12-19
- DOI:
- EISSN:
-
1098-6596
- ISSN:
-
0066-4804
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:1078428
- UUID:
-
uuid:67331a17-109a-4f2e-8407-85079043c524
- Local pid:
-
pubs:1078428
- Source identifiers:
-
1078428
- Deposit date:
-
2019-12-19
Terms of use
- Copyright holder:
- Crown copyright
- Copyright date:
- 2019
- Rights statement:
- © Crown copyright 2020. The government of Australia, Canada, or the UK ("the Crown") owns the copyright interests of authors who are government employees. The Crown Copyright is not transferable.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from the American Society for Microbiology at: https://doi.org/10.1128/AAC.02005-19
If you are the owner of this record, you can report an update to it here: Report update to this record